


Acute CHF treatment algorithm



*Placement of a peripheral vascular catheter facilitates the administration of intravenous medications and should be a high priority unless the animal is too unstable to tolerate it

Vetmedin 0.75 mg/ml solution for injection dose table:

Weight of dog:	5 kg	10 kg	15 kg	20 kg	25 kg	30 kg	35 kg	40 kg	45 kg	50 kg
Volume of injection:	1 ml	2 ml	3 ml	4 ml	5 ml	6 ml	7 ml	8 ml	9 ml	10 ml

CHF = congestive heart failure; MVD = mitral valve disease; DCM = dilated cardiomyopathy; i.v. = intravenous; i.m. = intramuscular; p.o. = per os; bpm = breaths per minute; RR = respiratory rate
† For full administration details, please consult furosemide SPC ** The preferable daily dose is 0.5mg/kg/day divided into 2 equal doses given 12 hours apart.

Developed in collaboration with
Andrew Brown MA VetMB DipACVECC MRCVS
RCVS Recognised Specialist in Emergency and Critical Care,
and **Ruth Willis** BVM&S DVC MRCVS
RCVS Recognised Specialist in Cardiology at:

Vetmedin 0.75 mg/ml solution for injection for dogs

Presentation: A clear, colourless solution for injection. Each ml contains 0.75 mg pimobendan.

Uses: To initiate treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

Dosage and administration: Single intravenous injection at a dosage of 0.15 mg pimobendan/kg body weight (i.e. 2 ml/10 kg body weight). A 5 ml and a 10 ml vial can treat up to a 25 kg and 50 kg bodyweight dog respectively. Each vial is for single use only. Vetmedin flavour tablets or Vetmedin hard capsules for dogs may be used for continuation of treatment at the recommended dosage, to be started 12 hours after administration of the injection.

Contra-indications, warnings, etc: The product should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).

In the event of accidental subcutaneous injection, temporary swelling and mild resorptive inflammatory reactions may occur at or below the injection site. For single administration only.

A moderate positive chronotropic effect and vomiting may occur in rare cases. In rare cases, transient diarrhoea, anorexia or lethargy have been observed.

In studies with rats and rabbits, pimobendan had no effect on fertility. Embryotoxic effects only occurred at maternotoxic doses. In rat experiments, it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits outweigh the potential risk.

In the case of overdose, symptomatic treatment should be initiated.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Operator warnings: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions: This product does not contain an antimicrobial preservative. This product is intended for single use only. Any product remaining in the bottle after withdrawal of the required dose should be discarded. Shelf-life of the veterinary medicinal product as packaged for sale: 36 months. Use immediately after opening.

Legal category: POM-V. **Marketing authorisation number:** Vm 00015/4082.

Vetmedin 1.25 mg and 5.0 mg Flavour Tablets, Vetmedin 5.0 mg Hard Capsules

Presentation: Vetmedin 5.0 mg hard capsules: Hard gelatine capsules white/orange to brown in colour, containing 5.0 mg pimobendan per capsule. Vetmedin 1.25 mg and 5.0 mg flavour tablets: Meat flavoured tablets containing 1.25 mg or 5.0 mg pimobendan per tablet.

Uses: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with furosemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

Contra-indications, warnings, etc: Vetmedin should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose. In rare cases, transient diarrhoea, anorexia or lethargy have been observed. In studies with rats and rabbits, pimobendan had no effect on fertility and embryotoxic effects occurred only at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk. No information is available on the safety of pimobendan in pregnant and lactating bitches.

The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β -antagonist propranolol. In pharmacological studies, no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.

In the case of overdose, symptomatic treatment should be initiated.

Any unused product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements. For animal treatment only. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use. Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

Legal category: POM-V. **Marketing authorisation number:** Vetmedin hard capsules 5.0 mg Vm 00015/4050; Vetmedin 1.25 mg flavour tablets Vm 00015/4077; Vetmedin 5.0 mg flavour tablets Vm 00015/4076.

Vetmedin contains pimobendan. Prescription only medicine. Further information available from Boehringer Ingelheim Vetmedica, Bracknell, Berkshire, RG12 8YS, UK. Tel: +44 (0)1344 746959. Email: vetmedica.uk@boehringer-ingelheim.com. Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: Dec 2012. AHD 7392.

Developed in collaboration with

Andrew Brown MA VetMB DipACVECC MRCVS

RCVS Recognised Specialist in Emergency and Critical Care,

and **Ruth Willis** BVM&S DVC MRCVS

RCVS Recognised Specialist in Cardiology at:



NEW
vetmedin INJECTION[®]
PRIMARY CARE